Business Context and Reporting Period
This Form 8-K filing by Collegium Pharmaceutical, Inc. covers the reporting period ending May 12, 2015. The report details corporate governance changes executed in connection with the closing of the Company's initial public offering (IPO).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on legal and structural amendments rather than financial performance data.
Material Changes
Effective May 12, 2015, the Company implemented the following material changes to its corporate structure:
- Articles of Incorporation: Filed amended and restated articles to increase authorized common stock to 100,000,000 shares, eliminate references to previous preferred stock, authorize 5,000,000 shares of undesignated preferred stock, and classify the Board of Directors.
- Bylaws: Adopted amended and restated bylaws that eliminate shareholder action by written consent, establish procedures for shareholder proposals and director nominations, and align with the new Articles of Incorporation.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies are discussed in this report, as it serves solely to disclose the adoption of the Post-IPO Charter and Restated Bylaws.
Investor Verification Checklist
- Verify the effective date of the new Articles of Incorporation and Bylaws (May 12, 2015).
- Confirm the total authorized common stock is now 100,000,000 shares.
- Note the elimination of the ability for shareholders to take action by written consent.
- Review the attached Exhibits 3.1 and 3.2 for the full text of the amended governing documents.